IDH1 and glioblastoma: These findings were further validated with the results of a published GBM IDH-WT study in patients evaluated for KDR amplification using FISH.20 In contrast to the UTHealth cohort and the published study by Burford et al.,20 both demonstrating a statistically significant association with survival, the MSK-IMPACT cohort demonstrated a trend toward shorter survival (16.6 vs 22.8 months) in KDR-amplified cases which was not statistically significant.